Neurocrine Biosciences (NBIX) Other Working Capital Changes (2011 - 2019)
Neurocrine Biosciences (NBIX) posted Other Working Capital Changes of $31.4 million for Q1 2026, up 12.95% on a QoQ basis from $27.8 million in Q4 2025, and up 4385.71% year-over-year from $700000.0 in Q1 2025.
Neurocrine Biosciences (NBIX) Other Working Capital Changes (2011 - 2019) Analysis & Trends
Neurocrine Biosciences' Other Working Capital Changes history runs 11 years deep, the most recent figure standing at $31.4 million for Q1 2026.
- Quarterly Other Working Capital Changes rose 4385.71% year-over-year to $31.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $75.1 million (up 46.39% YoY) and the FY2025 annual result came in at $44.4 million, down 17.78% from the prior year.
- Other Working Capital Changes was $31.4 million for Q1 2026 at Neurocrine Biosciences, up from $27.8 million in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $10.2 million in Q1 2015 and bottomed at -$9.7 million in Q4 2015.
- A 5-year average of $256571.4 and a median of $361000.0 in 2016 frame the typical range for Other Working Capital Changes.
- Annual changes were most pronounced in 2023 — Other Working Capital Changes tumbled 4860.0% — and 2026, when it jumped 4385.71%.
- Neurocrine Biosciences' Other Working Capital Changes stood at -$19.1 million in 2022, then surged by 252.36% to $29.1 million in 2023, then soared by 85.57% to $54.0 million in 2024, then tumbled by 48.52% to $27.8 million in 2025, then increased by 12.95% to $31.4 million in 2026.
- Business Quant data shows NBIX's Other Working Capital Changes at $31.4 million in Q1 2026, $27.8 million in Q4 2025, and $16.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 2.20 Mn |
| Sep 30, 2019 | 2.20 Mn |
| Sep 30, 2019 | 2.20 Mn |
| Jun 30, 2019 | -2.13 Mn |
| Jun 30, 2019 | -2.13 Mn |
| Jun 30, 2019 | -2.13 Mn |
| Mar 31, 2019 | 2.11 Mn |
| Mar 31, 2019 | 2.11 Mn |
| Mar 31, 2019 | 2.11 Mn |
| Sep 30, 2018 | -180,000.00 |
| Sep 30, 2018 | -180,000.00 |
| Sep 30, 2018 | -180,000.00 |
| Jun 30, 2018 | 2.45 Mn |
| Jun 30, 2018 | 2.45 Mn |
| Jun 30, 2018 | 2.45 Mn |
| Mar 31, 2018 | 441,000.00 |
| Mar 31, 2018 | 441,000.00 |
| Mar 31, 2018 | 441,000.00 |
| Dec 31, 2017 | -4.32 Mn |
| Dec 31, 2017 | -4.32 Mn |